Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AstraZeneca plc (AZN) vs Okta, Inc. (OKTA) Price & Performance

AstraZeneca plcTrade
Okta, Inc.Trade

Price performance (Past 24H)

Key statistics

AstraZeneca plc vs Okta, Inc. — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while Okta, Inc. trades at $147.43 (market cap $26.13B). The key difference: AstraZeneca plc is far larger — about 9.5× Okta, Inc.'s market cap, and AstraZeneca plc pays a 2.01% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals.

AZNOKTA
Market Cap
$248.14B$26.13B
Sector
HealthTechnology
52-Week High
$209.48$154.62
52-Week Low
$147.06$62.93
Enterprise Value
$275.41B$23.95B
Dividend Yield
2.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AstraZeneca plc

AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.

Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.

Okta, Inc.

Okta trades at $147.43, down 2.22% today, with a bullish technical signal from moving averages but overbought RSI readings. The company achieved GAAP profitability in 2025 with $28M net income, marking a significant turnaround from prior losses. Recent earnings beats and the acquisition of Permiso Security for AI identity threat defense highlight growth momentum. Operating cash flow surged to $750M in 2025, supporting financial flexibility.

The outlook is positive with strong analyst support (73% buy ratings) and a consensus price target of $129.71, though the current price exceeds this. Risks include high valuation multiples (P/E 108.93) and competitive pressure from Microsoft. Revenue growth to $3.0B in 2026 forecasts sustained expansion, but investor caution is warranted near technical resistance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN

About Okta, Inc.

Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.

Read more on OKTA